📚 Peer-Reviewed Research
Retatrutide is an investigational single-molecule agonist of the GIP, GLP-1, and glucagon receptors. Published research has evaluated its effects on body weight, glycemic control, gastric emptying, liver fat, body composition, safety, and tolerability. It remains under clinical development, and findings may evolve as additional trials are completed.​​​​
​
Triple-Hormone-Receptor Agonist Retatrutide for
Obesity —A Phase 2 Trial
​
Journal: New England Journal of Medicine
Published: 2023
Study Type: Phase 2 randomized, double-blind, placebo-controlled clinical trial
​
Summary
This 48-week study evaluated Retatrutide in 338 adults with obesity or overweight and at least one weight-related condition. Researchers reported dose-dependent reductions in body weight. Gastrointestinal effects were the most common adverse events, and temporary dose-dependent increases in heart rate were also observed.
​
Read Full Publication:
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
​
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/37366315/
​
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, in People With Type 2 Diabetes
​
Journal: The Lancet
Published: 2023
Study Type: Phase 2 randomized, double-blind, placebo- and active-controlled clinical trial
​
Summary
This study evaluated Retatrutide in adults with type 2 diabetes. Researchers examined changes in glycated hemoglobin, body weight, safety, and tolerability. The study reported clinically meaningful improvements in glycemic control and reductions in body weight, while gastrointestinal events were among the most frequently reported adverse effects.
​
Read Publication:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext
​
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/37385280/
​
Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
​
Journal: Nature Medicine
Published: 2024
Study Type: Randomized Phase 2a clinical substudy
​
Summary
This substudy included 98 participants from the Phase 2 obesity trial who had elevated liver fat. Researchers evaluated changes in liver-fat content during 48 weeks of treatment. Significant reductions were observed in the higher-dose groups, and liver-fat changes were associated with changes in body weight, abdominal fat, insulin sensitivity, and lipid metabolism.
​
Read Full Publication:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
​
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/38858523/
​
Effects of Retatrutide on Body Composition in People With Type 2 Diabetes
Journal: The Lancet Diabetes & Endocrinology
Published: 2025
Study Type: Body-composition substudy of a randomized Phase 2 trial
​
Summary
This analysis evaluated changes in fat mass and lean mass among adults with type 2 diabetes. Retatrutide produced greater reductions in total body-fat mass than placebo and dulaglutide. The proportion of lean-mass loss relative to total weight loss was reported as similar to that seen with other obesity treatments.
​
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/40609566/
​
The Novel GIP, GLP-1 and Glucagon Receptor Agonist Retatrutide Delays Gastric Emptying
Journal: Diabetes, Obesity and Metabolism
Published: 2023
Study Type: Original human pharmacology research
Summary
Researchers examined Retatrutide’s effects on gastric emptying. The findings showed delayed gastric emptying, providing mechanistic information about how the compound may influence nutrient absorption, post-meal glucose responses, appetite-related signaling, and gastrointestinal tolerability.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/37311727/
​
Current Clinical Development​
Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis: Rationale and Design of the TRIUMPH Trials
Journal: Diabetes, Obesity and Metabolism
Published: 2026
Study Type: Clinical trial design and development paper
Summary
This publication describes the rationale and design of the Phase 3 TRIUMPH clinical-trial program. The trials are evaluating Retatrutide across obesity and related conditions, including obstructive sleep apnea and knee osteoarthritis. This is a trial-design paper and should not be presented as completed efficacy evidence.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/41090431/
​
Review Articles
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Published: 2025
Study Type: Peer-reviewed scientific review
Summary
This review discusses Retatrutide’s triple-receptor mechanism and summarizes published findings involving body weight, glycemic control, metabolic outcomes, safety considerations, and remaining research questions. It is a review of existing evidence rather than a new clinical trial.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/40563436/
​
Efficacy and Safety of Retatrutide in Adults With Obesity
Published: 2025
Study Type: Systematic review and meta-analysis
Summary
This analysis combined available clinical evidence involving Retatrutide in adults with obesity. The authors reported improvements in body weight and several metabolic outcomes while emphasizing the need for larger and longer-duration trials to clarify long-term efficacy and safety.
Read Full Text:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
​
Additional Retatrutide Publications
​
Browse current PubMed results:
https://pubmed.ncbi.nlm.nih.gov/?term=retatrutide
​
Research Disclaimer
This Research Library summarizes published scientific literature for educational purposes only. Pearland Peptides products are intended For Research Use Only and are not for human consumption or medical use.